Nutriband Inc. Warrant - NTRBW STOCK NEWS

Nutriband Inc. reports a 48% increase in Q2 2023 revenues compared to Q2 2022, with quarterly revenue of $655,928. Stockholders' equity is $6.9 million as of July 31, 2023. The launch of AI Tape brand and partnership with Donovan McNabb as brand ambassador are seen as positive milestones for the company.

Nutriband engages Donovan McNabb as brand ambassador for AI Tape, targeting the $236M Elastic Therapeutic Tape market. McNabb's reputation as a pro athlete will deliver exposure and value to the brand. Global market expected to grow to $733.21M by 2033 with a CAGR of 12.0%.

Nutriband Inc. announces the launch of its consumer sports recovery tape brand, Active Intelligence AI Tape, now available for purchase on Amazon and Activeintell.com. AI Tape combines traditional benefits of kinesiology tape with soothing and therapeutic ingredients. Nutriband CEO, Gareth Sheridan, expresses excitement for the launch of the brand, targeting the consumer market. AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) reported financial results for the fiscal year ending January 31, 2023, highlighting a record revenue of $2.1 million, up 46% from the previous year. Key achievements include a favorable court verdict recovering 15% of total outstanding shares and the announcement of a Seven-for-Six Forward stock split. The company received patent allowance for its AVERSA™ technology in North America and partnered with Kindeva Drug Delivery for enhanced abuse-deterrent characteristics. Despite a net loss of $4.48 million (or $0.53 per share), down from $6.37 million in FY 2022, the results reflect significant operational progress. Research expenses increased to $0.98 million from $0.4 million, while SG&A expenses decreased slightly to $3.9 million. The company aims for commercial growth in 2023 and anticipates AVERSA™ to achieve annual sales between $80 million and $200 million.

Nutriband (NASDAQ:NTRB, NTRBW), recognized for its innovative transdermal solutions, is set to present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 08:30 AM PST. CEO Gareth Sheridan will lead the presentation, followed by a Q&A session.

To join the live presentation, access the webcast here. For those interested in one-on-one investor meetings during the event in Las Vegas, registration is available here.

Nutriband is advancing its abuse deterrent fentanyl patch utilizing the patented AVERSA technology, aimed at mitigating drug misuse and exposure risks.

Nutriband Inc. (NASDAQ:NTRB, NTRBW) announced a partnership with Kindeva Drug Delivery to advance the AVERSA™ Fentanyl formulation into commercial manufacturing. The AVERSA™ Fentanyl product utilizes Nutriband's proprietary abuse-deterrent technology and is projected to achieve peak U.S. sales between $80M and $200M. This collaboration aims to develop the first abuse-deterrent fentanyl patch, enhancing safety and accessibility for patients. The technology is supported by a robust intellectual property portfolio, with patents granted in multiple countries.